GI Innovation
GI Innovation is a South Korean biotechnology company focused on discovery and development of protein-based therapeutics and combination therapies. The organization develops leads and production cell lines using an automated high-throughput screening platform, pursues immune-modulating biologics (including agents that modulate NK and CD8+ T cells), and sponsors early-stage multi-site clinical trials in collaboration with academic centers and industry partners.
Industries
Nr. of Employees
medium (51-250)
Patents
Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain
US-12692307-B2
View DetailsPharmaceutical composition for enhancing radiotherapy comprising fusion protein containing IL-2 protein and CD80 protein
US-12478675-B2
View DetailsExtracellular domain of alpha subunit of IgE Fc receptor, pharmaceutical composition comprising same and method for producing same
US-12410233-B2
View DetailsPolypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of IGE FC receptor, and pharmaceutical composition comprising same
US-12409203-B2
View Details
Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain
US-12692307-B2
View DetailsPharmaceutical composition for enhancing radiotherapy comprising fusion protein containing IL-2 protein and CD80 protein
US-12478675-B2
View DetailsExtracellular domain of alpha subunit of IgE Fc receptor, pharmaceutical composition comprising same and method for producing same
US-12410233-B2
View DetailsPolypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of IGE FC receptor, and pharmaceutical composition comprising same
US-12409203-B2
View DetailsProducts
GI-101
Immuno-oncology therapeutic candidate in clinical development (early-phase studies).
GI-102
Immuno-oncology agent under clinical evaluation in combination regimens (including a phase 1b trial exploring combination with a KLK2-CD3 T-cell engager) and investigated at low doses for NK-cell enhancement in aging/healthspan studies.
GI-301
Therapeutic candidate for IgE-mediated allergic diseases.
GI-10N
Program in immuno-oncology (project-stage entry listed on company pipeline).
GI-30N
Program targeting allergic and fibrotic diseases (project-stage entry listed on company pipeline).
GI-20N
Program in development for metabolic disease indications (project-stage entry listed on company pipeline).
GI-101
Immuno-oncology therapeutic candidate in clinical development (early-phase studies).
GI-102
Immuno-oncology agent under clinical evaluation in combination regimens (including a phase 1b trial exploring combination with a KLK2-CD3 T-cell engager) and investigated at low doses for NK-cell enhancement in aging/healthspan studies.
GI-301
Therapeutic candidate for IgE-mediated allergic diseases.
GI-10N
Program in immuno-oncology (project-stage entry listed on company pipeline).
GI-30N
Program targeting allergic and fibrotic diseases (project-stage entry listed on company pipeline).
GI-20N
Program in development for metabolic disease indications (project-stage entry listed on company pipeline).
Expertise Areas
- Clinical trial management (early-phase, multi-site)
- Immuno-oncology
- Biologic discovery and engineering
- Bispecific antibody engineering
Key Technologies
- High-throughput screening (HTS)
- Bispecific antibody engineering
- Cell-line development for biologics
- Immune cell modulation (NK and CD8+ activation)
News & Updates
Announcement of a clinical supply agreement to evaluate a combination therapy in metastatic castration-resistant prostate cancer (phase 1b), with the company acting as sponsor and sites in Korea and the United States.
Selection as a Top 40 semi-finalist in the XPRIZE Healthspan competition for a combination approach using an immune-enhancing agent together with a synbiotic product; clinical collaboration and further trial funding noted.
Announcement that an investigational immuno-oncology agent received FDA Fast Track designation for metastatic urothelial carcinoma; includes early clinical response metrics from a combination trial.
Announcement of advancement in the XPRIZE Healthspan competition and description of a low-dose immune-boosting strategy combined with a microbiome product to address aging-related endpoints.
Announcement of a clinical supply agreement to evaluate a combination therapy in metastatic castration-resistant prostate cancer (phase 1b), with the company acting as sponsor and sites in Korea and the United States.
Selection as a Top 40 semi-finalist in the XPRIZE Healthspan competition for a combination approach using an immune-enhancing agent together with a synbiotic product; clinical collaboration and further trial funding noted.
Announcement that an investigational immuno-oncology agent received FDA Fast Track designation for metastatic urothelial carcinoma; includes early clinical response metrics from a combination trial.
Announcement of advancement in the XPRIZE Healthspan competition and description of a low-dose immune-boosting strategy combined with a microbiome product to address aging-related endpoints.